No advantage of continuous vs intermittent meropenem in crit

1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous

Related Keywords

Russia , Italy , Croatia , Kazakhstan , , Intermittent Administration Of Meropenem , Rating Level , Continuous Infusion , Intermittent Administration , Critically Ill Patients , Simplified Acute Physiology Score , Antibiotic , Continuous , Intermittent , Mercy , Meropenem , Sepsis , Septic Shock , Infectious Disease ,